Article
Potentials of anti-VEGF therapy in neovascular glaucoma
Search Medline for
Authors
Published: | September 21, 2010 |
---|
Outline
Text
Background: Causal therapeutic approaches to neovascular glaucome e.g. in diabetic retinopathy include destructive laser- and kryotechniques of both the retina and ciliary body. Although anti-VEGF therapy widens the therapeutic spectrum, its efficacy remains unproven.
Methods: Case presentations, review of the literature.
Results: An uncomparable potential to temporarily resolve neovascular vessels following intraocular phamacotherapy using Avastin justifies rapid and lasting introduction into the therapeutic catalogue in neovascular glaucoma; an irreplaceable time advantage in the long term therapy of the disease may result.
Conclusion: As the pathogenesis of neovascular glaucoma is not influenced causally or longer-lasting by intraocular Avastin, adjunctive and prompt application of the aforementioned established treatment modalities may help to approve or refund anti-VEGF therapy in neovascular glaucoma.